Current Status and Clinical Development of Transcatheter Approaches for Severe Mitral Regurgitation

Carmelo Grasso, MD; Davide Capodanno, MD, PhD; Corrado Tamburino, MD, PhD; Yohei Ohno, MD

Transcatheter mitral valve intervention has emerged as an effective treatment option for symptomatic severe mitral regurgitation in patients considered to be inoperable or at high operative risk for surgical mitral valve surgery. Most transcatheter approaches are modifications of existing surgical approaches. Transcatheter edge-to-edge mitral valve repair with the MitraClip system has the largest clinical experience to date, as it offers a sustained clinical benefit in selected patients. This review aims to provide an up-to-date overview of transcatheter mitral valve interventions, including leaflet repair, annuloplasty, and mitral valve implantation. (Circ J 2015; 79: 1164–1171)

Key Words: Annuloplasty; MitraClip; Mitral regurgitation; Transcatheter mitral valve implantation; Transcatheter mitral valve repair

Mitral regurgitation (MR) is one of the most common valvular heart diseases in Japan, as in other Western countries. A study in healthy Japanese subjects showed that 64.4% had any degree of MR, whereas the prevalence of clinically significant moderate-to-severe MR is reported to be approximately 1.7% in the general population of the United States, increasing with age to approximately 9.3% in those >75 years of age. The etiology of MR is diverse, and it may result from abnormalities in the structure and/or function of one or more components of the mitral apparatus (ie, leaflets, annulus, chordae tendineae, papillary muscles, and left ventricle [LV]). Degenerative MR (DMR) involves primary abnormalities of the leaflets, most commonly from myxomatous degeneration, whereas in secondary or functional MR (FMR), the leaflets are usually normal, and the regurgitation occurs as a consequence of adverse LV remodeling, with papillary muscle displacement, leaflet tethering, and annular dilatation.

Regardless of its etiology, severe MR is associated with progressive LV dysfunction and congestive heart failure, ultimately leading to high rates of morbidity and mortality. Current guidelines recommend surgery for moderate-to-severe (3+) or severe (4+) MR in patients with symptoms or evidence of LV dysfunction. However, when the MR is secondary to underlying LV dysfunction (ie, FMR), the benefit of surgery is controversial. Therefore, patients with FMR and high surgical risk are frequently denied surgery and referred to isolated clinical management, carrying a poor long-term prognosis. Indeed, the Cleveland Clinic database showed that among 1,095 symptomatic severe MR patients, 53% were deemed inoperable and were medically managed, with most of them (90%) presenting with FMR. Likewise, the Euro Heart Survey data revealed that almost half of symptomatic patients hospitalized with severe MR are not referred for surgery, mainly because of advanced age (>70 years), comorbidities, and LV dysfunction. On the other hand, a meta-analysis of mitral valve (MV) surgery in patients ≥80 years of age showed an association with high operative mortality (~15%), although this figure has decreased significantly in recent years. That study also demonstrated that MV repair suffers from lower operative mortality compared with MV replacement in octogenarians.

These data in aggregate suggest that there is a potentially large unmet need for transcatheter MV intervention in high surgical risk patients or those who are denied surgery because of comorbidities. Various technologies of intervention, at different stages of investigation, have been introduced to minimize surgical intervention and risks. These approaches can be mainly categorized into leaflet repair, annuloplasty, chordal implantation, and transcatheter MV implantation (TMVI) (Table 1).

Leaflet Repair

Among the transcatheter MV repair (TMVR) technologies, edge-to-edge MV repair with the MitraClip system (Abbott Vascular, Abbott Park, IL, USA) has undergone the most extensive human investigation thus far, with more than 20,000 procedures already performed. The MitraClip is a polyester-covered cobalt-chromium clip (Figures 1A,B) inserted via the femoral vein and advanced under transesophageal echocardiographic guidance into the left atrium following a transseptal puncture (Figure 1C). The clip is opened, positioned above the regurgitant jet, and advanced into the LV. It is then retracted...
Table 1. Transcatheter MV Intervention Devices Under Investigation

<table>
<thead>
<tr>
<th>Target of therapy</th>
<th>Device name &amp; manufacturer</th>
<th>Access route (size)</th>
<th>Mechanism of action</th>
<th>Clinical status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leaflet repair</td>
<td>MitraClip (Abbott Vascular, USA)</td>
<td>TV-TS (24Fr)</td>
<td>Clip-based edge-to-edge repair</td>
<td>CE mark approved FDA approved (DMR only)</td>
</tr>
<tr>
<td></td>
<td>MitraFlex (TransCardiac Therapeutics, USA)</td>
<td>TA</td>
<td>Automatic capturing and connection of the approximate midpoint of the leaflets/implantation of an artificial chordae tendinae</td>
<td>Preclinical study underway</td>
</tr>
<tr>
<td>Indirect annuloplasty</td>
<td>Carillon (Cardiac Dimensions, USA)</td>
<td>TJ (9Fr)</td>
<td>Coronary sinus reshaping</td>
<td>CE mark approved</td>
</tr>
<tr>
<td></td>
<td>Mitral Cerclage (NIH, USA)</td>
<td>TJ</td>
<td>Coronary sinus-right atrial encircling</td>
<td>Preclinical study underway</td>
</tr>
<tr>
<td></td>
<td>Valcare (Valcare Medical, Israel)</td>
<td>TJ</td>
<td>Rigid D-shaped annuloplasty</td>
<td>Preclinical study underway</td>
</tr>
<tr>
<td>Direct annuloplasty</td>
<td>Mitralign (Mitralign, USA)</td>
<td>TF</td>
<td>2×2 plicating anchors through posterior annulus</td>
<td>CE mark trial completed USA feasibility trial planned</td>
</tr>
<tr>
<td></td>
<td>Cardioband (Valtech, Israel)</td>
<td>TV-TS</td>
<td>Plicating anchors on atrial side of mitral annulus</td>
<td>CE mark trial underway</td>
</tr>
<tr>
<td></td>
<td>Accucinch (Guided Delivery Systems, USA)</td>
<td>TF</td>
<td>Plicating anchors on ventricular side of mitral annulus</td>
<td>International feasibility trial underway</td>
</tr>
<tr>
<td></td>
<td>Millipede (Millipede, USA)</td>
<td>TV-TS</td>
<td>Semirigid circumferential annular ring</td>
<td>Preclinical study underway</td>
</tr>
<tr>
<td>Chordal implantation</td>
<td>NeoChord (NeoChord, USA)</td>
<td>TA</td>
<td>Synthetic chordae tendinae</td>
<td>CE mark approved</td>
</tr>
<tr>
<td>MV implantation</td>
<td>CardiAQ (CardiAQ, USA)</td>
<td>TV-TS/TA (32Fr)</td>
<td>Self-positioning, self-anchoring, and self-conforming system for TMVI</td>
<td>First-in-man study completed</td>
</tr>
<tr>
<td></td>
<td>Fortis (Edwards, USA)</td>
<td>TA-TV-TS</td>
<td>TMVI technology designed to minimize PVL</td>
<td>First-in-man study completed</td>
</tr>
<tr>
<td></td>
<td>Tiara (Neovasc, USA)</td>
<td>TA-TV-TS (32Fr)</td>
<td>Self-expanding bovine pericardial, D-shaped trileaflet MV</td>
<td>First-in-man study completed</td>
</tr>
<tr>
<td></td>
<td>Tendyne (Tendyne Holdings, USA)</td>
<td>TA (30Fr)</td>
<td>Fully retrievable, self-expanding trileaflet porcine pericardial valve sewn onto a nitinol frame/atrial and ventricular fixation system</td>
<td>First-in-man study completed</td>
</tr>
<tr>
<td></td>
<td>Medtronic TMVR (Medtronic, USA)</td>
<td>TA/TV-TS</td>
<td>Self-expanding nitinol scaffold and a bovine pericardial valve with 3 cusps/recapturable and retrievable</td>
<td>Preclinical study underway</td>
</tr>
<tr>
<td></td>
<td>Cardiovalve (Valtech, Israel)</td>
<td>TV-TS (26Fr)</td>
<td>TMVI system that can be delivered using a TF delivery system in a 2-step implantation procedure</td>
<td>Preclinical study underway</td>
</tr>
</tbody>
</table>

DMR, degenerative mitral regurgitation; Fr, French; MV, mitral valve; PVL, paravalvular leakage; TA, transapical; TAt, transatrially; TF, transfemoral; TJ, transjugular; TMVI, transcatheter MV implantation; TS, transseptal; TV, transvenous.

Evidence From the EVEREST II Trial
The Endovascular Valve Edge-to-Edge REpair Study (EVEREST II) was a randomized, controlled trial conducted to evaluate the safety and effectiveness of the MitraClip compared with MV surgery (repair or replacement). The primary safety endpoint was the incidence of major adverse events (MAEs) at 30 days, whereas the primary efficacy endpoint was freedom from death, surgery for MV dysfunction, or MR grade ≥3+ at 12-month follow-up after clip implantation. The study cohort included DMR in 74% and FMR in 26% of patients. Acute device success, defined as residual MR ≤2+ after the procedure, was achieved in 77% of the patients. The study met its primary efficacy non-inferiority endpoint vs. surgery. Although MAEs were significantly lower in the device group (15% vs. 48%), this difference was almost entirely attributable to the inclusion of transfusion of ≥2 units of blood as an adverse event. At 5-year follow-up, patients treated with the MitraClip system were reported to more frequently require MV surgery to treat residual MR compared with the surgical group (25.7% vs. 7.5%), although no differences were observed after 1-year follow-up (presented by Kar S, EuroPCR 2014, unpublished data, Paris). In addition, no mortality differences were observed at 5-year follow-up (18.8% vs. 21.0%). Subgroup analysis of

to grasp the free edges of the mitral leaflets (Figures 1D,E), the grippers are dropped, and the clip is closed and released, imitating a surgical edge-to-edge repair that corrects the MR by suturing the leaflet edges at the site of regurgitation to create a double-orifice valve (Figure 1F). Multiple clips may be safely placed, if necessary. The MitraClip has CE mark approval for general use, and Food and Drug Administration approval in the United States for treatment of symptomatic patients with severe primary DMR at prohibitive risk for MV surgery, but it is not currently approved for secondary FMR.
mental components according to the SF-36 quality of life questionnaire, and annual hospitalization rates for heart failure reduced from 0.79% before the procedure to 0.41% post-procedure.

ACCESS-EU (MitraClip Therapy Economic and Clinical Outcomes Study Europe) is another recent multicenter study with a total of 567 patients at 14 European sites, which demonstrated an implant success rate of 99.6%.

The 30-day and 1-year mortality rates were 3.4% and 19%, respectively. By 1 year, open MV surgery was necessary in 6.3% of patients, 3.4% of patients required a second MitraClip procedure to treat residual MR, and the incidence of 3–4+ MR was 21%. Among the 1-year survivors, 71% were in NYHA functional class I/II with improvements in 6-min walk test and quality of life scores. Similar findings were demonstrated in the European Sentinel Registry, in which most patients treated were elderly, had multiple comorbidities, and were high-risk surgical candidates. Most patients in this cohort had FMR (72%). Acute procedural success was high (95.4%) and similar for FMR and DMR. In-hospital mortality was low (2.9%), without significant differences between groups. The estimated 1-year mortality was 15.3%, which was similar for FMR and DMR. Paired echocardiographic data of baseline and 1-year follow-up showed a persistent reduction in the degree of MR at 1 year.

MitraClip in Subsets of Interest

MitraClip therapy has been proven to maintain high rates of procedural success and to be clinically effective even in high-risk subsets. A retrospective multicenter analysis suggested a clear clinical benefit in 50 patients with LV ejection fraction ≤25%. The 6-month survival was 81.2% and improved functional class as well as LV reverse remodeling were demon-
stratified. In the European PERMIT-CARE (Percutaneous Mitral Valve Repair in Cardiac Resynchronization Therapy) trial, 51 severely symptomatic cardiac resynchronization therapy non-responders with significant FMR underwent device MitraClip therapy.\textsuperscript{23} Overall, 30-day mortality was 4.2%, and the procedure was shown to be feasible, safe, and effective in demonstrating significant MR reduction, LV reverse remodeling, and improved functional class. Data from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry\textsuperscript{24} has shown clinical benefits in severe symptomatic FMR patients with concomitant moderate/severe tricuspid regurgitation (TR) after MitraClip treatment (ie, improvement in MR, TR, and NYHA functional class). However, baseline moderate/severe TR remained an independent predictor for death and rehospitalization for heart failure at 12 months.\textsuperscript{25} Patients from the initial experiences, as well as the ones included in the randomized controlled trial, however, had to fulfill strict echocardiographic criteria to be considered suitable for MitraClip therapy, which largely limited its indications. A recently published GRASP substudy demonstrated that patients who fulfilled the criteria used in the EVEREST II trial and those who did not fulfill them showed similar safety at 30 days and efficacy through 12-month follow-up after MitraClip implantation.\textsuperscript{31} Furthermore, both groups revealed statistically significant LV reverse remodeling at 12 months, but the between-group baseline differences were sustained. Those results therefore suggest potential room for expanding the indications of MitraClip implantation beyond the initial criteria proposed by the EVEREST study.

**MitraClip: Current Status and Ongoing Directions**

In aggregate, the published MitraClip data from real-world clinical practice demonstrate consistent safety and high procedural success rates, high clinical efficacy, and improved functional status and quality of life in patients who are considered high risk for mitral surgery. Importantly, the 5-year follow-up of the EVEREST II trial has demonstrated that this device can favorably affect reverse remodeling in patients with DMR or FMR and no mitral annular dilatation up to at least 5 years despite annulus under-sizing not being achievable with the MitraClip device. The 2012 European Society of Cardiology/European Association for Cardio-Thoracic Surgery valve and heart failure guidelines provide a Class Ib (LOE: C) recommendation to consider MitraClip use in symptomatic patients with severe secondary MR, despite optimal medical therapy, and CRT, who are deemed inoperable or at high surgical risk.\textsuperscript{5} TMVR for secondary MR did not receive an official recommendation in the 2014 ACCF/AHA valvular heart disease guidelines, although it is currently recommended with Class Ib (LOE: B) guidance for severe primary MR in symptomatic patients at prohibitive risk for MV surgery.\textsuperscript{6}

In an attempt to expand these indications, 2 ongoing clinical trials are investigating the effectiveness of MitraClip for FMR patients after optimal medical therapy and CRT (if indicated). The COAPT (Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy) Trial for High Surgical Risk (www.clinicaltrials.gov, identifier NCT01626079) will be the first study to show whether reducing MR has any effect on mortality or other clinical outcomes in heart failure patients with FMR. The RESHAPE-HF (Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation) trial (www.clinicaltrials.gov, identifier NCT01772108) is a similar trial being conducted in Europe, which has been recently halted because of slow recruitment, with protocol modification ending with the initiation of the RESHAPE 2 study. While COAPT and RESHAPE 2 investigate the effectiveness of MitraClip in FMR patients beyond optimal medical therapy, the MATTERHORN (Mitra Valve Reconstruction for Advanced Insufficiency of Functional or Ischemic Origin) trial (www.clinicaltrials.gov, identifier NCT02371512) will compare MitraClip therapy and reconstructive MV surgery in patients with FMR. The results of these trials will clarify the role of the MitraClip in FMR.

### Table 2. MitraClip Registries: Baseline Characteristics, Acute Procedural Success, and 30-Day/1-Year Outcomes

<table>
<thead>
<tr>
<th>Registry</th>
<th>n</th>
<th>Age (years)</th>
<th>Risk Score*</th>
<th>NYHA III/IV</th>
<th>LVEF</th>
<th>FMR</th>
<th>Post MR ≤2+</th>
<th>30-day mortality</th>
<th>1-year mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRAMI\textsuperscript{16}</td>
<td>1,064</td>
<td>75</td>
<td>10%</td>
<td>87%</td>
<td>NA</td>
<td>71%</td>
<td>96%</td>
<td>5.7%</td>
<td>NA</td>
</tr>
<tr>
<td>European Sentinel\textsuperscript{17}</td>
<td>628</td>
<td>74</td>
<td>20%</td>
<td>86%</td>
<td>43%</td>
<td>72%</td>
<td>98%</td>
<td>3%</td>
<td>15.3%</td>
</tr>
<tr>
<td>ACCESS-EU\textsuperscript{18}</td>
<td>567</td>
<td>78</td>
<td>23%</td>
<td>85%</td>
<td>NA</td>
<td>77%</td>
<td>91%</td>
<td>3.4%</td>
<td>17.3%</td>
</tr>
<tr>
<td>EVEREST II and REALISM\textsuperscript{19}</td>
<td>351</td>
<td>76</td>
<td>11%</td>
<td>85%</td>
<td>48%</td>
<td>70%</td>
<td>86%</td>
<td>4.8%</td>
<td>22.8%</td>
</tr>
<tr>
<td>Treede et al\textsuperscript{20}</td>
<td>202</td>
<td>75</td>
<td>44%</td>
<td>98%</td>
<td>44%</td>
<td>65%</td>
<td>92%</td>
<td>3.5%</td>
<td>10.4%</td>
</tr>
<tr>
<td>GRASP\textsuperscript{21}</td>
<td>171</td>
<td>71</td>
<td>7%</td>
<td>81%</td>
<td>37%</td>
<td>78%</td>
<td>93%</td>
<td>0.9%</td>
<td>14%</td>
</tr>
<tr>
<td>Neuss et al\textsuperscript{22}</td>
<td>157</td>
<td>74</td>
<td>22%</td>
<td>100%</td>
<td>41%</td>
<td>73%</td>
<td>100%</td>
<td>7%</td>
<td>20%</td>
</tr>
<tr>
<td>MARS\textsuperscript{23}</td>
<td>142</td>
<td>71</td>
<td>17%</td>
<td>68%</td>
<td>47%</td>
<td>54%</td>
<td>77%</td>
<td>5.6%</td>
<td>NA</td>
</tr>
<tr>
<td>Bozdag-Turan et al\textsuperscript{24}</td>
<td>121</td>
<td>77</td>
<td>11%</td>
<td>96%</td>
<td>42%</td>
<td>59%</td>
<td>99%</td>
<td>3.3%</td>
<td>23.1%</td>
</tr>
<tr>
<td>Taramasso et al\textsuperscript{25}</td>
<td>109</td>
<td>69</td>
<td>22%</td>
<td>82%</td>
<td>28%</td>
<td>100%</td>
<td>87%</td>
<td>1.8%</td>
<td>NA</td>
</tr>
<tr>
<td>Rudolph et al\textsuperscript{26}</td>
<td>104</td>
<td>74</td>
<td>36%</td>
<td>100%</td>
<td>43%</td>
<td>66%</td>
<td>92%</td>
<td>3.8%</td>
<td>22%</td>
</tr>
<tr>
<td>MitraSwiss\textsuperscript{27}</td>
<td>100</td>
<td>77</td>
<td>17%</td>
<td>82%</td>
<td>48%</td>
<td>62%</td>
<td>85%</td>
<td>4%</td>
<td>15.4%</td>
</tr>
</tbody>
</table>

*Mean or median risk score calculated by Society of Thoracic Surgeons score for TRAMI, EVEREST II and REALISM, GRASP, and Bozdag-Turan et al; others by the logistic EUROSCORE. ACCESS-EU, MitraClip Therapy Economic and Clinical Outcomes Study Europe; EVEREST II, Endovascular Valve Edge-to-Edge REpair STudy; FMR, functional mitral regurgitation; GRASP, Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation; LVEF, left ventricular ejection fraction; MARS, MitraClip Asia-Pacific Registry; MR, mitral regurgitation; NYHA, New York Heart Association; REALISM, Real World Expanded Multi-center Study of the MitraClip System; TRAMI, Transcatheter Mitral Valve Interventions.
therefore both improve outcomes and expand the therapeutic indications for MitraClip therapy.

The coronary sinus (CS) encircles the posterior mitral annulus, and it may allow devices to be delivered and indirectly affect the posterior mitral annulus geometry. Although the CS approach is theoretically a favorable procedure, it has some important limitations. Indeed, the CS is variably located at a certain distance from the mitral annulus (frequently increased in the case of severe MR with annular dilation), and circumflex coronary artery compression has been frequently observed. The Carillon Mitral Contour System (Cardiac Dimension, Inc, Mitral Annuloplasty Indirect Annuloplasty Surgical plication of the mitral annulus with an undersized ring is the standard surgical treatment option for FMR and it is considered to be a key step in achieving effective and durable results after surgery. Lack of a reliable transcatheter annuloplasty device has so far affected eligibility for transcatheter interventions. In fact, up to one-third of patients screened for MitraClip are declined because of unfavorable anatomy, including annular dilatation. Transcatheter annuloplasty may therefore both improve outcomes and expand the therapeutic indications for MitraClip therapy.

The coronary sinus (CS) encircles the posterior mitral annulus, and it may allow devices to be delivered and indirectly affect the posterior mitral annulus geometry. Although the CS approach is theoretically a favorable procedure, it has some important limitations. Indeed, the CS is variably located at a certain distance from the mitral annulus (frequently increased in the case of severe MR with annular dilation), and circumflex coronary artery compression has been frequently observed. The Carillon Mitral Contour System (Cardiac Dimension, Inc,
Kirkland, WA, USA) (Figures 2A-B) consists of self-expandable nitinol semihelical distal and proximal anchors connected by a nitinol bridge that are placed in the great cardiac vein and proximal CS. Tension generated by the system results in cinching of the posterior mitral annulus tissue anteriorly. The device is implanted via the right internal jugular vein with a 9Fr delivery catheter and can be easily retrieved if MR reduction is not favorable or coronary artery compromise develops. A prospective, single-arm feasibility study named AMADEUS (CARILLON Mitral Anuloplasty Device European Union Study) was performed to examine the safety and efficacy of the Carillon device for the treatment of FMR. Treated patients demonstrated significant reduction in mitral annular diameter and MR by at least 1 grade and improvement in functional class and quality of life through 24 months follow-up. A second-generation device was used in the TITAN (The Transcatheter Implantation of the Carillon Mitral Anuloplasty Device) trial, a prospective, nonrandomized study in which 53 patients with symptomatic FMR were enrolled for Carillon device therapy; 36 patients (68%) underwent successful permanent device implantation, and 17 devices were not implanted because of insufficient valve leaflet retraction. A nonrandomized subset (n=9) or transient coronary compromise (n=8). Patients who received the device had significant reductions in MR grade, favorable LV remodeling, and improved quality of life. The Carillon device received CE mark approval in Europe in 2011. Successful MitraClip therapy after failure of transcatheter MV annuloplasty with the Carillon device has been reported. Recently reported, TITAN II was a prospective, single-arm, European multicenter clinical trial aimed at further evaluating an enhanced version of the Carillon system (presented by Haude M, TCT 2014, unpublished data, Washington DC). In the study, 30 patients at 5 sites were implanted with Carillon devices and were followed for 1 year. Enrolled patients represented a severely ill, advanced heart failure population at baseline. It showed significant reductions in FMR assessed by quantitative measures (ie, regurgitant volume) and a low 30-day MAE rate of 2.8%.

Direct Annuloplasty

Implantation of devices directly into the mitral annulus more closely reproduces surgical annuloplasty. Only the posterior annulus is usually targeted for this purpose, because the anterior annulus remains a more challenging structure with its anatomical proximity to the aortic valve. Annular calcification, the presence of the circumflex artery nearby, and the potential for leaflet damage remain of concern for direct annuloplasty approaches. Access to the annulus can be either through transseptal puncture or retrograde through the aortic valve and the LV. The Mitralign Percutaneous Annuloplasty System (Mitralign, Tewksbury, MA, USA) (Figures 2C-E) is based on surgical suture plication of the annulus. In this procedure, a deflectable catheter is advanced retrogradely to the LV and guidewires penetrate the mitral annulus into the left atrium, whereby pairs of pledgets are implanted in the posterior mitral annulus near the A1-P1 and A3-P3 scallops target points. Each pledget pair can be pulled together, resulting in a segmental posterior annuloplasty to shorten the annulus up to 17 mm. A prospective, single-arm feasibility and safety study is ongoing to obtain CE mark approval. Available data reported that 36 patients have been enrolled, and 24 treated; 5 of them have reached the 1-year follow-up. Although final results are not yet available, in the first 15 patients no procedural deaths and 1 case of cardiac tamponade occurred. After 1 year, an average reduction of 1 grade of MR was observed, together with minimal reduction in LV dimensions.

The Cardioband System (Valtech Cardio Ltd, Or Yehuda, Israel) (Figures 2F,G) is a percutaneous-implantable surgical-like ring. Different from the previous devices, and similar to the MitraClip, it is delivered anterogradely via transseptal atrial access. Therefore, the ring is implanted in the atrial side of the mitral annulus. The Cardioband is a polyester prosthetic tube (band) sequentially fixed by helical anchors, from the anterolateral to the posteromedial trine; after implantation, the annular circumference is reduced by controlling tension on the band under echo-guidance, thereby reducing the degree of MR. Early animal studies demonstrated the safety and feasibility in the device, and several patients have already had successful percutaneous implants. The 6-month follow-up data on patients implanted with the system at 6 sites throughout Europe was recently reported (presented by Nickeneg G, ACC 2015, unpublished data, San Diego). It demonstrated a 100% procedural success rate in 35 patients, with more than 80% of patients experiencing a sustained reduction in the severity of FMR, improvements to NYHA functional class, 6-min walking test results and quality of life among patients, with no incidences of procedural mortality, severe bleeding or cardiac tamponade.

Chordal Implantation

A different approach to achieving transcatheter leaflet repair is off-pump adjustable chordal implantation. Synthetic chords can be implanted via a transapical or transseptal approach and are anchored between the LV myocardium and the leaflet. By adjusting the length of the chord, the MR can be reduced. This approach would be mainly for DMR.

The NeoChord system (Neochord, Inc, Minnetonka, MN, USA) is the only CE mark approved device, which places an anchor in the inner LV myocardium and another on the leaflet via a transapical approach and connects the 2 with a synthetic chord. The Transapical Artificial Chordae Tendinae (TACT) phase I clinical study with NeoChord enrolled 30 patients at 7 centers in Europe. The procedure has been demonstrated to be a safe and effective minimally invasive alternative to open surgical repair in selected patients with mitral leaflet prolapse (flail/chordae rupture). More than 150 patients have been treated to date.

Transcatheter Mitral Valve Implantation

Since the introduction of transcatheter aortic valve implantation (TAVI), there has been an emerging growth of interest in percutaneous approaches to other valvular diseases. TMVI may have the potential to become an alternative to treating severe MR in high surgical risk patients because of its theoretical possibility to reduce MR to a similar extent as surgery while reducing procedural risks. Transcatheter heart valves for antegrade transapical and apical delivery are currently being tested in bench and preclinical models. Clinical experience with these devices remains scarce. Although the use of TAVI valves in the mitral position in patients with dysfunctional mitral bioprosthetic valves and annuloplasty rings has shown feasibility and proof of concept, there remain many challenges in treating the diseased native MV. The MV anatomy carries unique and complex features that make TMVI much more challenging than TAVI. The mitral annulus is asymmetrical, nontubular, and frequently not calcified; therefore, anchoring of the bioprosthesis...
to the mitral annulus would be a problem because radial force would not be effective and could cause serious complications. LV outflow tract obstruction and aortic valve deformation (that could derive from a large and rigid mitral stent) are also major concerns. Moreover, leaks in the mitral position would be poorly tolerated, both hemodynamically and in terms of hemolysis because of the elevated pressure gradients. MV implantation is not yet routinely available in the clinical setting, but several devices are currently under development. Although multiple technical challenges are still present, technological evolution will likely overcome these challenges and enable this procedure to be a valuable alternative to MV surgery for high surgical risk patients.

Conclusions

Transcatheter approaches for severe MR have emerged during the past decade as a viable, less invasive therapeutic option in patients with high surgical risk. TMVR with the MitraClip system has proven excellent safety and good efficacy in high-risk patients and is already considered as a mature procedure when performed in experienced centers. Other TMVR devices are still in their early experiences. TMVI aims to become a technically simple and reproducible procedure. However, durability, safety and possible disruption of adjacent cardiac structures remain important concerns. It is important to emphasize that novel transcatheter techniques for the treatment of MR are not meant to replace surgical techniques in lower risk patients who are good candidates for surgery. Because various transcatheter MV intervention devices will be available in the future, it is of particular importance to understand how to tailor the right device or strategy to the right patient and clinical setting. Careful patient selection with the heart-team approach will undoubtedly play a critical role in defining the clinical niche for successful transcatheter interventions.

Funding Sources

Y.O. is supported by a grant from the Japan Heart Foundation and Bayer Yakuhin Research Grant Abroad.

Disclosures

C.G. is a proctor for Abbott Vascular. D.C. has received consulting honoraria from Abbott Vascular. All the other authors have no relationships relevant to the contents of this paper to disclose.

References


